February 7, 2020
Mylan issued an alert regarding the manufacturing challenges in the production of EpiPen (epinephrine injection, USP) 0.3 mg and EpiPen Jr (epinephrine Injection, USP) 0.15 mg auto-injectors and the authorized generic versions of these strengths. These challenges resulted in the reduced availability of these product.
VDP temporarily removed the non-preferred status from the following:
|00093598627||Epinephrine 0.3 mg auto-injector|
This change will allow providers to prescribe these product NDCs without requiring non-preferred prior authorization and allow continued access to medication. The current preferred NDCs are:
|00093598527||Epinephrine 0.15 mg auto-injector|
|00115169449||Epinephrine 0.3 mg auto-injector|
|00115169549||Epinephrine 0.15 mg auto-injector|
|49502010101||Epinephrine 0.15 Mg auto-injector|
|49502010102||Epinephrine 0.15 Mg auto-injector|
|49502010201||Epinephrine 0.3 Mg auto-injector|
|49502010202||Epinephrine 0.3 Mg auto-injector|
This is a temporary change until the preferred products are sufficiently available again in the market. VDP confirmed there may be outages varying between pharmacies despite Mylan products no longer identified as a shortage according to FDA and ASHP. VDP will send out further announcements regarding future PDL status changes of these NDCs.